
DMRA
Healthcare · Biotechnology · $1.34B market cap
$21.60-0.45 (-2.0%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 4, 2026 | After the close | -0.52 | -0.40 | +23.1% |
| Aug 10, 2026 | After the close | -0.38 | -0.39 | -2.6% |
| May 13, 2026 | Time not confirmed | -0.65 | -0.81 | -24.6% |
| Mar 20, 2026 | Time not confirmed | -0.11 | 2.31 | +2236.9% |
| Nov 7, 2025 | Time not confirmed | — | -2.36 | — |
| Aug 6, 2025 | Time not confirmed | — | -2.60 | — |
| May 9, 2025 | Time not confirmed | — | -1.92 | — |
| Mar 19, 2025 | After the close | -3.12 | -5.22 | -67.3% |
| Nov 1, 2024 | Before the open | -3.70 | -3.39 | +8.4% |
| Aug 12, 2024 | After the close | -6.00 | -5.00 | +16.7% |
| Apr 29, 2024 | After the close | -4.25 | -5.00 | -17.6% |
| Mar 25, 2024 | Time not confirmed | — | -5.97 | — |
| Nov 6, 2023 | After the close | -12.12 | -4.99 |
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address…
| +58.8% |
| Jul 31, 2023 | After the close | -14.67 | -10.25 | +30.1% |
| Apr 28, 2023 | Time not confirmed | — | -12.65 | — |
| Mar 9, 2023 | Before the open | -14.25 | -13.75 | +3.5% |
| Nov 8, 2022 | Before the open | -17.00 | -13.50 | +20.6% |
| Jul 29, 2022 | Before the open | -17.25 | -16.75 | +2.9% |
| Apr 29, 2022 | Time not confirmed | — | -16.76 | — |
| Feb 17, 2022 | After the close | -14.00 | -13.25 | +5.4% |
| Nov 4, 2021 | After the close | -14.00 | -12.50 | +10.7% |
| Aug 5, 2021 | Before the open | -13.50 | -12.25 | +9.3% |
| May 4, 2021 | Before the open | -11.50 | -13.25 | -15.2% |
| Mar 29, 2021 | Time not confirmed | — | -3.89 | — |
| Dec 11, 2020 | Before the open | -502.75 | -1381.25 | -174.7% |